TARGET-D 203 trial: what clinicians have said so far
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- NCT07659795 ↗
- Recruiting
- Verastem, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on TARGET-D 203 (VS-7375; VS-7375 plus cetuximab; VS-7375 plus cetuximab plus mFOLFOX6 in metastatic KRAS G12D-mutated colorectal adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TARGET-D 203 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X, typically up to 22 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Colorectal Cancer
- Interventions
- VS-7375; cetuximab; panitumumab; Cetuximab + mFOLFOX6
- Arms
- VS-7375 Monotherapy or Preferred Combination in 2L+ CRC · Experimental
- VS-7375 with chosen regimen in 2L+ CRC · Experimental
- VS-7375 + cetuximab and mFOLFOX in 1L CRC · Experimental
- Enrollment
- 150 (estimated)
- Primary outcomes
- Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only
- To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC
- To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC
- Sponsor
- Verastem, Inc.
- Start
- Jul 28, 2026
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07659795 · updated Nov 18, 2026